Ypsomed Holding AG
0QLQ.L
London Stock Exchange355.40
CHF
-4.00
- -
Ypsomed Holding AG
0QLQ.L
(London Stock Exchange)
Recent
price
355.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ypsomed Holding AG (SIX: YPSN) develops and manufactures customized injection systems for the self-administration of liquid medications, serving as a leading partner to pharmaceutical and biotech companies worldwide. The company offers a comprehensive portfolio of platforms including disposable and reusable pens, autoinjectors such as YpsoMate (with variants up to 5.5 ml), on-body devices like YpsoDose and YpsoFlow, and sustainable innovations such as YpsoLoop for circularity and YpsoMate Zero with zero carbon emissions; it also provides end-to-end services encompassing human factors engineering, regulatory affairs, testing, quality assurance, sustainability support, contract manufacturing, and digital health integrations like SmartPilot connectivity add-on. Ypsomed operates manufacturing facilities in Switzerland (Burgdorf, Solothurn), Germany (Schwerin), China (Changzhou), and is establishing a new site in the United States (Holly Springs, North Carolina), targeting global markets for chronic conditions including diabetes, obesity, and biologics therapies. Founded in 1984 and headquartered in Burgdorf, Switzerland, the company employs over 2,000 people across its global network. In recent strategic shifts, Ypsomed sold its diabetes care business (Ypsomed Diabetes Care AG) to TecMed AG for up to CHF 420 million in July 2025, positioning itself as a pure-play self-injection systems provider; it also divested Ypsotec to Callista in October 2025 and earlier pen needle/blood glucose monitoring operations to MTD. The company continues aggressive expansion with new production halls in Schwerin (Germany, second plant topping-out in 2025), site openings in China (June 2025), and U.S. facility investments exceeding CHF 200 million, alongside partnerships such as long-term autoinjector supply with Novo Nordisk, collaborations with BD for high-viscosity biologics, Sidekick Health for obesity digital solutions, and product launches like the first dual GCG/GLP-1 agonist in China via Innovent Biologics.